证券代码：600285 证券简称：羚锐制药 公告编号：2023-044 号 河南羚锐制药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （600285@lingrui.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 河南羚锐制药股份有限公司（以下简称"公司"）于 2023 年 8 月 10 日发布 公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年 度经营成果、财务状况，公司计划于 2023 年 08 月 21 日下午 15:00-16:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 08 月 21 日 下午 15:00-16 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2023-023 河南羚锐制药股份有限公司 关于召开 2022 年度业绩说明会的公告 本次投资者说明会以视频录播结合网络互动召开，公司将针对 2022 年度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 05 月 23 日下午 15:00-16:30 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 23 日(星期二)下午 15:00-16:30 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频录播和网络互动 投资者可于 2023 年 05 月 16 日(星期二)至 05 月 22 日(星期一)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通 ...

Financial Performance - The company achieved operating revenue of CNY 300,186.22 million, representing a year-on-year growth of 11.45%[7] - Net profit attributable to shareholders reached CNY 46,533.08 million, with a year-on-year increase of 28.71%[7] - The weighted average return on equity increased by 3.36 percentage points to 19.28%[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 134,217,849.64 in Q2, showing a growth compared to Q1[3] - The net cash flow from operating activities was CNY 217,358,967.28 in Q2, indicating strong cash generation capabilities[3] - The company's revenue for 2022 reached approximately ¥3.00 billion, representing an increase of 11.45% compared to ¥2.69 billion in 2021[66] - Net profit attributable to shareholders for 2022 was approximately ¥465.33 million, a growth of 28.71% from ¥361.54 million in 2021[66] - The net cash flow from operating activities for 2022 was approximately ¥834.91 million, showing a slight decrease of 1.27% compared to ¥845.69 million in 2021[66] - The company's total assets as of the end of 2022 were approximately ¥4.34 billion, reflecting a 14.53% increase from ¥3.79 billion at the end of 2021[66] - The basic earnings per share for 2022 was ¥0.836, an increase of 28.62% from ¥0.650 in 2021[67] Market Position and Product Development - The market share of the "Two Tigers" series products ranks first in their respective categories, with specific products achieving market shares of 92.59% and 48.36%[15] - The company is focusing on R&D for core traditional Chinese medicine products and has initiated five new projects related to the molecular mechanisms of traditional medicine[15] - The company has a diverse product line, including pain relief patches and capsules for chronic diseases, with key products such as 通络祛痛膏 and 培元通脑胶囊[54] - The company is the only domestic producer of fentanyl transdermal patches, which are expected to have a strong market outlook due to their ease of use and lower adverse reactions compared to injections[23] - New product developments include traditional Chinese medicine formulations for pain relief and chronic conditions, with some products included in national and provincial medical insurance catalogs[118] - The company plans to launch new respiratory products, such as Qing Shi granules, to expand its product line and meet the growing consumer demand for personalized health services[164] Research and Development - The company plans to strengthen its R&D team and invest in automation and digitalization to ensure consistent quality control of raw materials and finished products[28] - Research and development expenses rose by 45.08% to CNY 125.07 million, reflecting the company's commitment to innovation[77] - The company invested ¥56,349.57 million in R&D, accounting for 6.26% of its total revenue[136] - The R&D investment as a percentage of net assets was 4.97%[136] - R&D personnel accounted for 20.25% of the total workforce, with 246 employees engaged in R&D activities[100] - The company will adopt a combined approach of in-house and outsourced research and development to enhance the efficiency of new product development and mitigate associated risks[170] Marketing and Sales Strategy - The company has implemented a marketing strategy that emphasizes self-operated promotions, covering all 31 provinces and regions in China[11] - The company aims to enhance its brand presence through various marketing campaigns and has received industry awards for its products[11] - The company established a comprehensive marketing network and improved digital marketing platforms, leading to rapid growth in online business revenue[73] - The company is focusing on expanding its market presence through partnerships with major online pharmacies like Alibaba Health and JD Pharmacy[73] - The company has made significant investments in marketing management to improve sales efficiency and effectiveness[141] Industry Trends and Outlook - The pharmaceutical industry is experiencing a long-term positive trend due to increasing health management demands driven by an aging population, with China's GDP growing by 3.0% in 2022, reaching 121 trillion yuan[16] - By the end of 2022, over 1.3 billion people in China were covered by basic medical insurance, stabilizing the coverage rate at over 95%, which supports the growth of pharmaceutical demand[16] - The aging population in China, with 28 million people aged 60 and above, is expected to drive demand for healthcare and related products, supporting industry growth[153] - The company anticipates potential risks from policy changes in the pharmaceutical industry, including procurement and payment reforms, which may intensify market competition[167] Corporate Governance and Compliance - The company has established a sound corporate governance structure, ensuring compliance with relevant laws and regulations, enhancing operational quality[173] - The board of directors has clear responsibilities, with all members fulfilling their duties responsibly, and no conflicts of interest reported[178] - The company maintains independence from its controlling shareholder, with no interference in operational activities[178] - The company has implemented effective internal control mechanisms to manage daily operations and ensure compliance with governance standards[179] - The company's information disclosure practices are in line with regulatory requirements, with timely and accurate reporting of financial results[179] Financial Management - The company plans to distribute a cash dividend of RMB 0.60 per share (including tax), totaling RMB 338,456,013.00, which represents 72.73% of the net profit attributable to shareholders in the consolidated financial statements[49] - The total share capital of the company is 567,299,680 shares, with 564,093,355 shares participating in the dividend distribution after excluding shares in the repurchase account[49] - The total cost for the manufacturing sector was 82,480,000 CNY, accounting for 99.19% of total costs, an increase of 20.55% compared to the previous year[87] - The company's accounts receivable financing increased by 116.37% to 64,686,589.47, attributed to an increase in bank acceptance bills[104] - Cash and cash equivalents at the end of the period amounted to 1,179,295,676.75, representing 27.15% of total assets, an increase of 47.18% compared to the previous period[104] Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[11] - The company faces cost volatility risks due to fluctuations in the prices of traditional Chinese medicinal materials, which may impact operational costs[168] - The company plans to optimize sales channels and cost-effectiveness to enhance profitability in the future[141]

Financial Performance - Net profit attributable to shareholders increased by 10.30% to ¥144,246,384.90[5] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 31.71% to ¥137,935,222.71, mainly due to an increase in operating income[6] - Operating revenue increased by 15.62% to ¥788,648,249.06[5] - Basic earnings per share rose by 9.70% to ¥0.260[5] - Diluted earnings per share increased by 10.92% to ¥0.254[5] - Net profit for the period reached ¥144,180,298.27, compared to ¥130,703,737.36 in the previous period, reflecting a growth of approximately 10.3%[28] - Total comprehensive income attributable to the parent company for Q1 2023 was ¥144,438,296.32, compared to ¥141,931,560.56 in Q1 2022, showing a slight increase of 3.6%[46] Assets and Liabilities - Total assets increased by 3.39% to ¥4,491,462,147.19 compared to the end of the previous year[2] - The company's total assets increased to ¥4,491,462,147.19 from ¥4,344,382,669.23, marking a rise of about 3.4%[27] - The equity attributable to shareholders of the parent company grew to ¥2,698,987,708.12, up from ¥2,550,918,961.13, which is an increase of approximately 5.8%[27] - The total liabilities as of Q1 2023 were ¥1,784,981,313.28, a slight decrease from ¥1,785,916,842.12 in Q1 2022[54] - The company recorded a total liability and equity of ¥4,491,462,147.19, consistent with the total assets, indicating a balanced financial position[27] Cash Flow - Net cash flow from operating activities decreased by 5.60% to ¥81,521,628.54[5] - Net cash generated from operating activities was ¥836,158,048.46 in Q1 2023, compared to ¥629,898,482.07 in Q1 2022, indicating a significant increase of 32.8%[57] - The net increase in cash and cash equivalents for Q1 2023 was ¥241,987,944.29, contrasting with a decrease of ¥47,538,320.80 in Q1 2022[49] - Operating cash inflow totaled CNY 873,767,046.56, an increase from CNY 668,624,954.82 in the previous period, reflecting a growth of approximately 30.7%[59] - Operating cash outflow amounted to CNY 792,245,418.02, compared to CNY 582,266,126.03, indicating an increase of about 36.0%[59] - Cash inflow from investment activities reached CNY 269,457,277.50, a decrease from CNY 280,069,462.48, showing a decline of approximately 2.2%[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,330[3] - The company repurchased and canceled 159,312 restricted stocks, adjusting the total number of granted restricted stocks to 13,211,288[23] Expenses - Total operating costs for Q1 2023 were ¥622,764,688.53, up 10.1% from ¥565,337,386.79 in Q1 2022[44] - Research and development expenses increased to ¥21,205,202.59 in Q1 2023, compared to ¥20,140,886.19 in Q1 2022, reflecting a growth of 5.3%[44] - Sales expenses for Q1 2023 amounted to ¥376,349,019.13, an increase of 14.5% from ¥328,590,129.99 in Q1 2022[44] - Cash paid to employees increased to CNY 77,976,112.17 from CNY 62,791,788.93, marking a rise of approximately 24.2%[59] - Taxes paid rose to CNY 146,557,715.10 from CNY 94,317,303.04, indicating an increase of around 55.4%[59] Other Financial Metrics - The weighted average return on equity decreased by 0.08 percentage points to 5.50%[2] - Interest income increased to ¥6,559,323.78 from ¥5,077,301.07, showing a growth of about 29.2%[28] - The company reported a financial expense of -¥5,819,501.33, compared to -¥3,642,842.09 in the previous period, indicating an increase in financial costs[28] - Other comprehensive income after tax for the period was ¥204,257.86, compared to ¥11,162,985.63 in the previous period, showing a significant decrease[28] - The company’s long-term equity investments remained stable at ¥71,690,947.15, slightly up from ¥71,652,345.36[26]

Financial Performance - The company's operating revenue for Q3 2022 was ¥774,345,720.40, representing an increase of 11.01% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥134,827,539.03, reflecting a growth of 25.93% year-over-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥128,686,535.24, with a year-over-year increase of 24.00%[7]. - The basic earnings per share for Q3 2022 was ¥0.243, up by 28.57% compared to the same period last year[11]. - The diluted earnings per share for Q3 2022 was ¥0.236, an increase of 27.57% year-over-year[11]. - Total operating revenue for the first three quarters of 2022 reached ¥2,277,024,517.97, an increase of 10.9% compared to ¥2,053,040,234.42 in the same period of 2021[35]. - Net profit attributable to shareholders of the parent company for Q3 2022 was ¥405,415,302.27, up 23.7% from ¥327,555,622.87 in Q3 2021[38]. - The total comprehensive income for Q3 2022 was ¥395,758,779.73, an increase of 26.8% from ¥311,938,445.97 in Q3 2021[41]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥4,101,139,526.85, which is an increase of 8.12% from the end of the previous year[11]. - The equity attributable to shareholders at the end of Q3 2022 was ¥2,445,759,727.64, reflecting a growth of 7.32% compared to the previous year[11]. - The company's total assets amounted to ¥4,101,139,526.85, compared to ¥3,793,087,404.03 in the previous year, reflecting a growth of 8.1%[35]. - The total current liabilities were CNY 1,578,034,170.94, compared to CNY 1,437,648,177.54 in the previous year, marking an increase of about 9.8%[32]. - The total liabilities amounted to CNY 1,647,707,560.48, compared to CNY 1,506,512,237.97 in the previous year, indicating a rise of about 9.3%[32]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥478,524,825.72, showing a decrease of 23.89%[11]. - The company reported a net cash inflow from operating activities of ¥2,417,437,578.46, slightly down from ¥2,433,894,109.37 in the same period of 2021[42]. - Operating cash inflow totaled $2,487,828,704.05, slightly down from $2,493,773,487.81 in the previous period[43]. - Operating cash outflow increased to $2,009,303,878.33 from $1,865,078,309.49, resulting in a net cash flow from operating activities of $478,524,825.72, down from $628,695,178.32[43]. - The net cash flow from investment activities was $166,220,807.69, a recovery from a negative $172,423,104.56 in the previous period[43]. - The net cash flow from financing activities was negative at -$324,915,930.88, compared to -$258,973,538.41 previously[46]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,112[19]. Research and Development - Research and development expenses for the first three quarters of 2022 were ¥68,187,400.25, an increase of 9.3% from ¥62,042,225.21 in the same period of 2021[35]. Other Financial Metrics - The company's cash and cash equivalents amounted to CNY 1,121,151,010.27, up from CNY 801,242,132.87 in the previous year, indicating a year-over-year increase of about 39.9%[26]. - Accounts receivable increased to CNY 266,795,621.48 from CNY 172,905,827.85, reflecting a growth of approximately 54.3%[26]. - The company's retained earnings reached CNY 1,341,996,603.11, an increase from CNY 1,218,777,634.44, representing a growth of approximately 10.1%[32]. - The company reported a significant increase in other receivables, which rose to CNY 40,108,444.73 from CNY 9,345,173.92, reflecting a growth of approximately 329.5%[26]. - Sales expenses for the first three quarters of 2022 were ¥1,091,706,144.65, an increase of 9.9% from ¥992,923,866.20 in the previous year[35]. Government Subsidies and Tax - The company received government subsidies amounting to ¥4,344,802.77 during the reporting period, totaling ¥32,676,609.86 for the year-to-date[12]. - The company received tax refunds amounting to $714,965.22 during the reporting period[43]. - Cash paid for various taxes rose to $316,727,958.78 from $282,751,594.30, indicating higher tax obligations[43]. Labor Costs - Cash paid to employees increased to $241,729,316.33 from $180,142,554.32, reflecting a rise in labor costs[43]. Product Development - The company has not disclosed any new product developments or market expansion strategies during the reporting period[24].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,502,678,797.57, representing a 10.86% increase compared to the same period last year[23]. - The net profit attributable to shareholders of the listed company was ¥270,517,763.14, an increase of 23.15% year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥238,943,470.50, reflecting a 15.31% increase compared to the previous year[23]. - Basic earnings per share for the first half of 2022 were ¥0.490, up 25.64% from ¥0.390 in the same period last year[23]. - The total profit for the first half of 2022 was CNY 313,526,002.13, compared to CNY 262,465,668.33 in the previous year, marking an increase of approximately 19.5%[147]. - The company reported a significant increase in investment income from joint ventures and associates, amounting to CNY 105,623,705.46, compared to CNY 20,775,669.20 in the previous year, which is an increase of over 408%[151]. Cash Flow and Assets - The net cash flow from operating activities decreased by 42.38% to ¥303,717,796.07, primarily due to a decrease in cash received from sales and an increase in cash paid for purchases[26]. - The company's cash and cash equivalents at the end of the reporting period were CNY 921,929,240.40, compared to CNY 769,177,982.26 at the beginning of the period, representing a growth of 19.8%[141]. - The company's cash and cash equivalents decreased significantly by 89.21% to 30,242,591.07 CNY, mainly due to the redemption of financial products held at the end of the previous period[67]. - The total assets at the end of the reporting period were ¥3,969,775,054.33, a 4.66% increase from the end of the previous year[23]. - The company's total assets reached CNY 4,000,289,013.27, an increase from CNY 3,837,132,512.56 at the beginning of the period, reflecting a growth of 4.2%[143]. Market and Industry Insights - The company operates in the pharmaceutical manufacturing industry, with 45 products listed in the national medical insurance directory and 24 in the essential drug list[31]. - The pharmaceutical manufacturing industry in China saw a revenue of 1,147.66 billion with a year-on-year growth of 2.3% from January to May 2022[39]. - The total profit in the pharmaceutical manufacturing sector decreased by 20.6% year-on-year, totaling 182.72 billion[39]. - The prevalence of musculoskeletal disorders in China increased from 25.0‰ in 2008 to 36.8‰ in 2018, indicating a growing market demand for effective pain management solutions[41]. - The chronic disease incidence rate for musculoskeletal disorders rose from 31% in 2008 to 58.6% in 2018, reflecting an increasing patient population and market opportunity[46]. Product Development and R&D - The company is actively developing new products and conducting evidence-based medical research to support chronic disease management, addressing the needs of key demographics[49]. - Research and development expenses amounted to 42,094,879.93 CNY, reflecting a 7.57% increase from the previous year[60]. - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[196]. - The company has allocated CNY 18,885,930.00 for new technology research and development initiatives[195]. Environmental and Social Responsibility - The company and its subsidiaries strictly adhered to national environmental policies, enhancing environmental management and employee awareness, with no environmental pollution incidents or administrative penalties reported[94]. - The company implemented comprehensive pollution control measures, ensuring that wastewater and exhaust emissions met regulatory standards[98]. - The company developed advanced energy-saving and environmentally friendly facilities, such as a heat pump concentration unit, to reduce energy consumption[99]. - The company’s solid waste management included using medicinal residues as organic fertilizer for ecological agriculture[99]. Shareholder and Corporate Structure - There were no significant changes in the company's stock or shareholder structure during the reporting period[21]. - The total number of shares decreased from 567,758,992 to 567,458,992 due to the repurchase and cancellation of 300,000 restricted stocks[119]. - The largest shareholder, Henan Lingrui Group Co., Ltd., holds 121,817,898 shares, accounting for 21.47% of the total shares, with 72,044,315 shares pledged[122]. - The company has not disclosed any major related party transactions during the reporting period[112].

证券代码：600285 证券简称：羚锐制药 公告编号：临 2022-022 号 河南羚锐制药股份有限公司 关于参加河南辖区上市公司 2022 年投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，河南羚锐制药股份有限公司定于 2022 年 5 月 30 日（周一）15:30-17:00 参加在全景网举办的"真诚沟通 传递价值" 河南辖区上市公司 2022 年投资者网上集体接待日活动，本次活动将采用网络远 程的方式举行，投资者可登录"全景•路演天下"（http://rs.p5w.net）参与本 次互动交流。 出席本次网上集体接待日活动的人员有：公司董事长熊伟先生、董事兼董事 会秘书冯国鑫先生、财务总监余鹏先生（如有特殊情况，参会人员将可能进行调 整）。届时公司管理层将通过网络在线问答互动的形式，与投资者就其关注的问 题进行交流。欢迎广大投资者积极参与。 特此公告。 河南羚锐制药股份有限公司董事会 二〇二二年五月二十五日 1 ...

Financial Performance - The company's operating revenue for 2021 was CNY 2,693,510,918.29, representing a 15.52% increase compared to CNY 2,331,577,446.95 in 2020[23] - The net profit attributable to shareholders of the listed company was CNY 361,542,665.62, an increase of 11.08% from CNY 325,489,250.98 in the previous year[23] - The net profit after deducting non-recurring gains and losses was CNY 354,810,538.61, reflecting an 18.46% increase from CNY 299,508,041.36 in 2020[23] - The net profit attributable to shareholders of the listed company for the fourth quarter was significantly lower due to increased costs and the write-off of non-current assets[30] - The net cash flow from operating activities increased to ¥845,686,168.39, representing a 87.71% increase compared to the previous year[26] - The total assets grew by 9.70% year-on-year, reaching ¥3,793,087,404.03 at the end of 2021[26] - Basic earnings per share increased by 13.44% to ¥0.650 compared to the previous year[26] - The total profit reached 413 million yuan, reflecting a year-on-year growth of 13.50%[37] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.50 per share, totaling approximately CNY 282,126,333.50 based on the adjusted share count[6] - The company does not plan to issue bonus shares or convert capital reserves into share capital for this reporting period[6] - The total number of shares for profit distribution is calculated based on the total share capital minus the shares held in the repurchase account[6] - The company has committed to maintaining the same per-share distribution amount, with adjustments to the total distribution amount if the number of shares changes due to employee stock plans[6] Risk Management - The company has not reported any significant risks that could materially affect its operations during the reporting period[7] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[7] Audit and Compliance - The company has maintained a standard unqualified audit opinion from its accounting firm, Dahua Certified Public Accountants[5] - The company has established various production and operating licenses for its pharmaceutical products, ensuring compliance with regulatory standards[134] - The company has established a transparent information disclosure system, ensuring timely and accurate reporting of financial and operational information[165] Research and Development - The company has increased its R&D investment, focusing on chemical patches, orthopedics, and cardiovascular fields, while also advancing the development of medical devices and health products[119] - The company’s R&D investment amounted to 54,463.68 million RMB, representing 7.14% of operating revenue and 5.97% of net assets[128] - The number of R&D personnel is 240, representing 19.30% of the total workforce[103] - R&D expenses decreased by 11.82% to ¥86,206,247.14 in 2021 from ¥97,763,376.06 in 2020, with total R&D investment accounting for 3.26% of operating revenue[102] Market Position and Product Development - The company developed and registered new products, including the bat moth fungus mycelium powder ginseng capsules and various vitamin and mineral capsules[38] - The company expanded its sales channels, developing over 7,800 hospitals nationwide during the reporting period[39] - The sales revenue of the Qianqi Jiangtang capsules and Danlu Tongdu tablets exceeded 100 million yuan[39] - The company was recognized as a "National Technology Innovation Demonstration Enterprise" and its patch factory was designated as a "2021 Henan Province Smart Factory"[42] Employee and Management Structure - The total number of employees in the parent company and major subsidiaries is 2,500, with 1,240 in the parent company and 1,260 in subsidiaries[192] - The company has 213 retired employees for whom it bears costs[192] - The workforce includes 714 production staff, 922 sales personnel, 370 technical staff, 109 financial staff, and 385 administrative staff[192] - The educational background of employees shows 34 with master's degrees or above, 451 with bachelor's degrees, 796 with associate degrees, and 1,219 with education below associate level[192] Governance and Board Activities - The company has established a sound corporate governance structure, ensuring compliance with relevant laws and regulations[161] - The board of directors operates effectively, with clear responsibilities and adherence to legal procedures for meetings and decision-making[164] - The company held six board meetings during the year, with all resolutions passed without any objections[183] - The Audit Committee held four meetings during the reporting period, approving all proposed resolutions[187] Sales and Marketing Strategies - The company has established a comprehensive marketing network, enhancing online sales through partnerships with platforms like Alibaba Health and JD Pharmacy[77] - The company plans to enhance its brand influence through strategic investments in brand promotion and channel development, focusing on chronic diseases and anesthesia markets[144] - The company aims to maintain competitive salary levels compared to industry peers and regularly adjusts compensation based on market comparisons[195] Challenges and Future Outlook - The company anticipates potential risks from policy changes in the pharmaceutical industry, including procurement and reimbursement adjustments[155] - The company faces cost fluctuation risks due to the volatility in the production and pricing of traditional Chinese medicine materials, influenced by external factors such as policies and climate[159] - New drug development involves high investment, high risk, and long cycles, with uncertainties in market prospects and economic returns[159]

2022 年第一季度报告 单位：元 币种：人民币 证券代码：600285 证券简称：羚锐制药 河南羚锐制药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 682,122,590.57 | ...

Financial Performance - The company's operating revenue for Q3 2021 was ¥697,553,750.78, representing a year-on-year increase of 21.34%[8] - The net profit attributable to shareholders for Q3 2021 was ¥107,069,514.37, an increase of 16.13% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥103,777,266.82, up 18.67% year-on-year[8] - The basic earnings per share for Q3 2021 was ¥0.189, reflecting a growth of 16.67% compared to the previous year[12] - Total operating revenue for the first three quarters of 2021 reached ¥2,053,040,234.42, an increase of 17.4% compared to ¥1,749,409,044.15 in the same period of 2020[38] - Net profit for the first three quarters of 2021 was ¥327,555,622.87, representing a growth of 22.0% compared to ¥268,309,852.21 in 2020[43] - The company reported a total profit of ¥376,322,413.97, an increase of 19.6% from ¥314,683,087.91 in the same period of 2020[43] Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥3,715,555,734.23, an increase of 7.46% from the end of the previous year[12] - As of September 30, 2021, the company's total assets reached RMB 3,715,555,734.23, an increase from RMB 3,457,756,227.25 as of December 31, 2020, representing a growth of approximately 7.46%[29] - Total current liabilities increased to RMB 1,389,245,214.96 from RMB 1,066,257,112.24, reflecting a rise of approximately 30.3%[35] - The total equity attributable to shareholders at the end of Q3 2021 was ¥2,243,078,725.55, a decrease of 3.01% compared to the previous year[12] - Total liabilities amounted to approximately $1.14 billion, with a slight increase from the previous period[56] - Non-current liabilities totaled approximately $69.34 million, reflecting an increase of about $8.41 million[56] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥628,695,178.32, showing an increase of 85.92%[12] - Cash inflow from operating activities totaled ¥2,493,773,487.81, a significant increase from ¥1,901,664,281.56 in the previous year[45] - The net cash flow from operating activities increased to ¥628,695,178.32, up from ¥338,148,814.79, representing an 86% increase year-over-year[49] - The net cash flow from investing activities was negative at -¥172,423,104.56, worsening from -¥60,773,584.28 in the previous year[49] - Cash inflow from financing activities totaled ¥235,906,400.00, an increase from ¥171,511,000.00 in the prior year[49] - Cash outflow for operating activities totaled ¥1,865,078,309.49, compared to ¥1,563,515,466.77, indicating a 19.3% increase[49] - The company reported a significant increase in tax payments, totaling ¥282,751,594.30, up from ¥241,435,349.15, which is a 17% increase[49] Shareholder Information - The company had a total of 34,572 common shareholders at the end of the reporting period[19] - The company repurchased a total of 19,086,325 shares, accounting for 3.36% of the total share capital, with a total expenditure of RMB 184,472,831.57 as of September 30, 2021[24] - The company completed the transfer of 2,159,400 shares under the employee stock ownership plan and granted 13,720,600 shares of restricted stock as part of its incentive plan[25] Expenses - Research and development expenses rose to ¥62,042,225.21, up 24.8% from ¥49,662,393.86 in the same period last year[38] - Sales expenses increased to ¥992,923,866.20, compared to ¥873,153,976.85 in the previous year, marking a rise of 13.7%[38] Accounting Policies - The company adopted the new leasing standards effective January 1, 2021, impacting the recognition of right-of-use assets and lease liabilities[57] - The accounting policy change is not expected to significantly affect the company's financial position, operating results, or cash flows[59] - The company confirmed the recognition of depreciation and interest expenses for all leased assets, excluding short-term and low-value leases[57] - The board of directors announced that the accounting policy change does not harm the interests of the company and its shareholders[59] Other Financial Metrics - The company's cash and cash equivalents amounted to RMB 929,602,638.19, up from RMB 732,316,860.77 in the previous year, indicating a year-over-year increase of about 27.0%[29] - The company's inventory as of September 30, 2021, was RMB 389,545,855.71, compared to RMB 331,412,309.59 at the end of 2020, marking an increase of around 17.5%[29] - The company's accounts receivable increased to RMB 269,562,213.59 from RMB 145,719,962.51, representing a significant growth of approximately 84.8%[29] - The company's long-term equity investments rose to RMB 116,572,532.76 from RMB 98,580,891.15, reflecting an increase of about 18.3%[33] - The company reported a total of RMB 934,975,900.94 in other payables, which increased from RMB 662,066,894.27, indicating a rise of approximately 41.1%[35] - Deferred income amounted to approximately $48.26 million, indicating stable revenue recognition practices[56] - The company maintains undistributed profits of approximately $1.13 billion, reflecting strong retained earnings[56]